<DOC>
	<DOC>NCT02042833</DOC>
	<brief_summary>This observational study will evaluate patients' perception of treatment with erythropoiesis-stimulating agents in patients with chronic kidney disease not on dialysis. Eligible patients initiated on treatment with Mircera (methoxy polyethylene glycol-epoetin beta) will be followed for 6 months.</brief_summary>
	<brief_title>An Observational Study of Patients' Perception of Treatment With Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease Not on Dialysis (PERCEPOLIS)</brief_title>
	<detailed_description />
	<mesh_term>Hematinics</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Patients with chronic kidney disease not on dialysis (with or without previous renal transplantation) Treated or not with ESA at time of visit Patients for whom the treating physician had decided to initiate Mircera for medical reasons before the commencement of the study Initiation of treatment with Mircera at the inclusion visit Accepting and able of completing the ESA preference questionnaire Participation in a clinical trial on anemia Treatment with Mircera during the 3 months before inclusion Dialysis planned in the next 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>